Pelthos Therapeutics Inc.
PTHS- Exchange
- NYSE
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001919246
In the last 90 days, Pelthos Therapeutics Inc. insiders filed 0 open-market purchases and 3 sales; 24 institutions reported holding it in 13F filings for Q2 2026, worth $37.4M in total; no superinvestor holds it.
Q1 2025 vs. Q4 2024
How the institutions holding Pelthos Therapeutics Inc. changed between Q4 2024 and Q1 2025.
All holders in Q1 2025All holders in Q4 2024
| Measure | Q4 2024 | Q1 2025 | Change |
|---|---|---|---|
| Holders | 4 | 9 | +5 |
| Shares | 25.0K | 595.9K | +570.9K (+2,282.5%) |
| Value | $16.0K | $846.2K | +$830.1K (+5,178.0%) |
New holders (6)
Institutions that held Pelthos Therapeutics Inc. at the end of Q1 2025 but not at the end of Q4 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Ikarian Capital, LLC | 440,849 | $626.0K | 0.20% |
| Boothbay Fund Management, LLC | 130,754 | $185.7K | 0.01% |
| Geode Capital Management, LLC | 10,070 | $14.3K | 0.00% |
| UBS Group AG | 995 | $1.41K | 0.00% |
| Tradewinds Capital Management, LLC | 200 | $284 | 0.00% |
| Barclays PLC | 54 | $77 | 0.00% |
Sold out (1)
Institutions that held Pelthos Therapeutics Inc. at the end of Q4 2024 and filed for Q1 2025 without it.
| Institution | Shares, Q4 2024 | Value, Q4 2024 |
|---|---|---|
| Two Sigma Securities, LLC | 14,347 | $9.20K |